Winter CME Series: Hematologic Malignancies (Update from ASH)

The University of Illinois Cancer Center is hosting its second annual Winter CME Series. Join us January 15 for Session 1 of the three-part series. Earn up to three hours of CME per session. The series is accredited by Global Education Group.

Register at the conference website: cmersvp.com/uicmew

The target audience includes medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals and other providers interested in the care of patients with cancer.

PRELIMINARY SESSION AGENDA
1 – 2 p.m. Registration, Exhibits and Lunch
2 – 2:05 pm Introduction
2:05 – 2:50 p.m. Update on novel treatment strategies including bispecific T-Cell engagers in Non-Hodgkin Lymphoma (Paul Rubinstein, MD – University of Illinois Cancer Center)
2:50 – 3:35 p.m. Review the advances in cellular therapy for the treatment of Non-Hodgkin Lymphoma and Leukemias (Carlos Galvez, MD – University of Illinois Cancer Center)
3:35 – 4:35 p.m. Break, Exhibits, Non-CME Ancillary Event, Afternoon Pick Me Up
4:35 – 5:20 p.m. Updates on Myeloma treatment including the use of Minimal Residual Disease (Francesca Cottini, MD – Ohio State University Comprehensive Cancer Center)
5:20 – 6:05 p.m. OPEN FORUM: Latest treatments in ALL and AML (Noah Birch, MD and John Quigley, MD – University of Illinois Cancer Center)
6:05 – 7 p.m. Exhibits

SERIES COURSE CHAIR
Matias E Sanchez, MD
Assistant Professor of Medicine
UI Health Division Hematology/Oncology
University of Illinois Cancer Center
Chicago, IL

SESSION 1 CHAIR
Carlos Galvez, MD
Assistant Professor of Medicine
UI Health Division Hematology/Oncology
Chicago, IL

FACULTY PRESENTERS
Noah Birch, MD
University of Illinois Cancer Center
Chicago, IL

Francesca Cottini, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

Carlos Galvez, MD
UI Health
Chicago, IL

John Quigley, MD
University of Illinois Cancer Center
Chicago, IL

Paul Rubinstein, MD
University of Illinois Cancer Center
Chicago, IL

EDUCATIONAL GOAL
This session aims to educate practitioners and update their knowledge of advances in diagnosing and managing Hematologic Malignancies.

LEARNING OBJECTIVES
After participating in these activities, learners will be better able to:
• Discuss the advancements and optimal strategies for the use of bispecific T-cell engagers and other novel therapies in Non-Hodgkin Lymphoma
• Understand the novel advancements in CAR T Cell Therapy for Non-Hodgkin Lymphoma and Leukemias
• Explain how to optimize treatment selection in Multiple Myeloma, including the use of minimal residual disease in the therapeutic setting
• Recommend the latest treatment approaches in Acute Lymphoblastic and Acute Myeloid Leukemia